GlassScriptPhysician profile
Sean Fischer
NPI 1801842943
$3,863.18
in general payments reported to CMS, 2019-2025
11 companies · $494 in 2025
The $494 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2022: $348 · 2023: $2,213 · 2024: $709 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,965 · Food and Beverage: $404 · Education: $47.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,965.00 |
| Food and Beverage | $403.55 |
| Education | $47.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,715.00 | 2023-2024 | Calquence |
| Glaxosmithkline, LLC. | $250.00 | 2025 | Blenrep |
| Novocure Gmbh | $200.00 | 2022 | |
| Histosonics, INC. | $188.67 | 2025 | |
| Lilly USA, LLC | $141.22 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $135.00 | 2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $71.56 | 2022-2025 | Keytruda, Lynparza |
| Pfizer INC. | $30.65 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2024 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.